International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.8026166
Original Article
Serum Ferritin Levels in Acute Myocardial Infarction: An Examination of Prognostic Significance
 ,
 ,
 ,
 ,
 ,
Published
June 12, 2023
Abstract
Background: Elevated serum ferritin levels have been associated with acute myocardial infarction (AMI), but its prognostic significance remains unclear. This study aimed to investigate the serum ferritin levels in patients with AMI and to explore its prognostic importance. Methods: This study involved patients admitted to Navodaya Medical College Hospital and Research Centre, Raichur, with confirmed AMI, and age and gender-matched controls. Serum ferritin levels were measured at presentation and at a 4-week follow-up. Clinical features, co-morbidities, habits, and echocardiographic findings were also recorded. Results: Serum ferritin levels were significantly elevated in patients with AMI at presentation (mean: 319.38, SD: 94.75) and at a 4-week follow-up (mean: 327.99, SD: 105.81) compared to controls (p < 0.0001). There was no significant difference in serum ferritin levels across different categories of left ventricular ejection fraction (p = 0.762103). The presence or absence of co-morbidities such as hypertension and diabetes, and habits like smoking and alcoholism, did not significantly influence serum ferritin levels. Conclusion: Our study suggests that serum ferritin levels are significantly elevated in patients with AMI and these elevated levels persist even at a 4-week follow-up. However, these levels did not correlate with left ventricular ejection fraction or with the presence or absence of certain co-morbidities and habits. Future studies are needed to further explore these relationships and the potential prognostic role of serum ferritin in AMI.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
2402 Views
400 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved